U.S. Life Sciences Stock News

What is moving Applied Optoelectronics right now? Applied Optoelectronics (AAOI) has been drawing attention after a sharp share price move, with the stock returning 119% over the past month and 272% over the past 3 months. For investors, these rapid swings put a spotlight on how the business fundamentals, including recent revenue and net income trends, line up with the current US$95.34 share price. See our latest analysis for Applied Optoelectronics. That recent surge sits on top of a much...

New CEO’s transformation plan puts Ichor Holdings (ICHR) in focus A leadership shift at Ichor Holdings (NasdaqGS:ICHR), with a new CEO prioritizing operational discipline, margin expansion, and core semiconductor activities, has pushed the stock into the spotlight for investors reassessing the story. See our latest analysis for Ichor Holdings. The recent leadership change comes after a powerful run in Ichor Holdings’ share price, with a 90 day share price return of 159.2% and year to date...

Core Scientific (CORZ) just posted its FY 2025 Q4 numbers, reporting revenue of US$79.8 million, basic EPS of US$0.68 and net income of US$216.0 million. The company has seen quarterly revenue move in a tight band between US$78.6 million and US$95.4 million since late 2024, while basic EPS has swung from a loss of US$1.17 per share in 2024 Q3 to a profit of US$0.68 in 2025 Q4, highlighting how volatile margins have been for shareholders tracking the story. With trailing twelve month EPS still...

Enovis Corporation recently reported its fourth-quarter and full-year 2025 results, including sales of US$575.76 million for the quarter and US$2.25 billion for the year, alongside a goodwill impairment charge of US$501.31 million that kept the company in a loss-making position. At the same time, Enovis issued 2026 guidance calling for US$2.31 billion to US$2.37 billion in revenue and 4–6% organic growth, highlighting how ongoing product innovation and margin efforts are being weighed...

If you are wondering whether Church & Dwight is offering fair value at its current share price, you are not alone. This article is built to help you assess what you are really paying for. The stock last closed at US$103.02, with a 7.0% return over the past 30 days, a 24.7% return year to date, but a 5.7% decline over the past year and longer term returns of 27.6% over 3 years and 35.9% over 5 years. Recent interest in Church & Dwight reflects its position as a long established household...

Everpure has changed its corporate name from Pure Storage Inc. to Everpure Inc. The change follows a certificate of amendment filed in Delaware. The company continues to trade under ticker NYSE:PSTG for now. For investors following NYSE:PSTG, the formal shift to Everpure Inc. signals that management wants the brand to reflect its current identity and priorities. The business remains centered on data storage and related solutions, an area that continues to attract attention as organizations...

IonQ acquired SkyWater Technology, a U.S. based quantum foundry, creating what it describes as a vertically integrated, full stack trapped ion quantum platform with domestic manufacturing. The company deployed the Romanian National Quantum Communication Infrastructure, one of the largest quantum secure networks in Europe. These moves expand IonQ's role across quantum computing, networking, and security, and may influence how investors assess its competitive position. IonQ (NYSE:IONQ) is...

Okta recently reported past-quarter results showing revenue and adjusted earnings growth, driven largely by enterprise uptake of its newer AI-focused security tools and identity offerings. The launch of Auth0 for AI Agents and an expanded AI security partnership with the PGA of America highlight Okta’s push into securing emerging AI-driven workloads and user experiences. With Okta leaning further into AI identity security via Auth0 for AI Agents, we’ll now examine how this reshapes its...

Wondering whether Stoke Therapeutics at around US$33.78 is starting to look expensive or if there is still value on the table? This article walks through the key numbers so you can judge for yourself. The stock has been volatile, with a 4.8% decline over the last 7 days, an 11.3% gain over 30 days, a 9.3% return year to date, a 345.6% return over 1 year, a 266.0% return over 3 years, and a 34.9% decline over 5 years. These price swings sit against a backdrop of ongoing attention on Stoke...

If you are looking at AGNC Investment and wondering whether the current share price gives you enough value for the risk you are taking, this article is built to walk you through that question step by step. The stock last closed at US$11.00, with returns of 2.7% decline over 7 days, 3.5% decline over 30 days, a 0.6% gain year to date, 24.4% over 1 year, 62.2% over 3 years, and 31.3% over 5 years. Recent price moves have been accompanied by ongoing attention on AGNC Investment's interest rate...

Fidelis Insurance Holdings Limited recently reported past fourth quarter 2025 results showing revenue of US$600.9 million and net income of US$117.8 million, alongside a full-year profit of US$225.5 million, while also maintaining its quarterly dividend at US$0.15 per share. At the same time, Fidelis completed and expanded sizeable share repurchase programs, including an agreement to buy all remaining shares held by founding shareholder CVC Falcon Holdings at US$19.00 per share, a price...

Formula One Group (FWON.K) is back on investors’ radar after year-end results showed higher revenue and a return to profit, alongside a fresh five-year Concorde Agreement and expanded global media partnerships. See our latest analysis for Formula One Group. At a share price of US$88.81, Formula One Group has given investors a 1-year total shareholder return decline of 2.5%, although the 3-year and 5-year total shareholder returns of 28.2% and 100.5% suggest longer term holders have seen...

CACI International (NYSE:CACI) has announced and priced a $500 million senior notes offering. The company plans to use the proceeds to help fund its acquisition of ARKA Group L.P. The transaction affects CACI International's capital structure and future debt obligations. For investors watching NYSE:CACI, this new senior notes offering comes at a time when the stock is trading at $629.75. The shares show longer term returns of 78.4% over the past year, 110.5% over three years, and 182.1%...

If you are wondering whether Palantir Technologies' current share price still makes sense after everything that has happened with the stock, this article will walk you through what the current market price could be implying about its value. The stock closed at US$147.22, with returns of 9.7% over the last 7 days, a 0.4% decline over 30 days, a 12.3% decline year to date, 63.3% over 1 year, and a very large gain over 3 years, which naturally raises questions about how much optimism is already...

Conference appearance puts U.S. Gold in focus U.S. Gold (USAU) is set to present at the Emerging Growth Virtual Conference on February 25, 2026. Executive Chairman Luke Anthony Norman is expected to speak, drawing attention to potential commentary on projects and capital needs. See our latest analysis for U.S. Gold. At a share price of US$18.84, U.S. Gold has seen a 7 day share price return of 4.96% and a 30 day share price return of 8.65%. The 1 year total shareholder return of 125.90% and 3...

Agios Pharmaceuticals recently announced that the Emirates Drug Establishment in the UAE approved PYRUKYND (mitapivat) as the first and only medicine for adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. This approval, supported by global Phase 3 ENERGIZE and ENERGIZE-T data and backed by a regional partnership with NewBridge Pharmaceuticals, strengthens Agios’s push into Gulf markets for rare blood disorder treatments. Next, we’ll examine...

If you are wondering whether Ross Stores is still good value after its run in the market, it helps to separate the share price story from what the underlying business may be worth. The stock last closed at US$197.64, with a 1.5% decline over 7 days, a 4.8% gain over 30 days, and returns of 8.2% year to date, 47.0% over 1 year, 85.9% over 3 years, and 67.2% over 5 years. This naturally raises questions about what is already priced in. Recent coverage around Ross Stores has largely focused on...

Axos Financial (AX) has been in focus after higher than expected inflation data raised doubts about near term rate cuts, putting pressure on bank stocks and sharpening investor attention on interest rate risk. See our latest analysis for Axos Financial. Despite the inflation driven sell off that recently hit Axos Financial, the current US$89.97 share price sits above its 90 day level, and the 1 year and 3 year total shareholder returns of 39.92% and 97.82% suggest momentum has been positive...

Why Twilio’s latest earnings and KPN partnership are drawing fresh attention Twilio (TWLO) is back on investors’ radar after fourth quarter results came in ahead of guidance, organic revenue growth impressed analysts, and fresh Buy ratings followed, helped by expanding AI focused products and the new RCS partnership with KPN Netherlands. See our latest analysis for Twilio. At a share price of $123.51, Twilio has seen an 8.48% 7 day share price return but a 10.73% decline year to date. The 1...

Aflac stock after recent performance Aflac (AFL) has been relatively steady in recent trading, with a 1-day return of about a 0.8% decline and a flat move over the past week, keeping investors focused on its longer-term record. See our latest analysis for Aflac. At a share price of US$112.43, Aflac’s recent pullback sits against a firmer backdrop, with a 30 day share price return of 1.33% and a 5 year total shareholder return of 151.14%. This suggests sentiment has been supportive over time...

Harry Potter tie-in puts McCormick’s Butterbeer flavors in focus McCormick (MKC) is back in the spotlight after partnering with Warner Bros. Discovery to launch limited edition Harry Potter Butterbeer Finishing Sugar and Butterbeer Flavor across major retailers. The collaboration gives investors a fresh data point on how licensing deals and themed products might influence McCormick’s broad consumer portfolio, which already spans spices, sauces, seasonings, and dessert products worldwide. See...

AbbVie recently reported positive topline Phase 3 results from its AFFIRM trial, showing risankizumab (SKYRIZI) subcutaneous induction led to significantly higher clinical remission and endoscopic response rates than placebo in adults with moderately to severely active Crohn’s disease, with safety consistent with prior data. Because AFFIRM included patients who had already failed multiple advanced therapies, the results highlight SKYRIZI’s potential to address a difficult-to-treat Crohn’s...

The Morning Bull - US Market Morning Update Wednesday, Mar, 4 2026 US stock futures are slightly softer this morning, with E-mini S&P 500 contracts down about 0.2%, as investors juggle stubborn inflation worries and mixed global growth signals. The US 10 year Treasury yield is holding near 4.06%, which indicates borrowing costs remain relatively high and keeps pressure on areas like real estate and smaller, debt heavy companies. At the same time, a large 5.6 million barrel build in US oil...

What Medline’s recent fundamentals mean for investors Medline (MDLN) has drawn fresh attention after investors focused on its latest reported fundamentals, including US$28.4b in revenue, US$1.2b in net income, and single digit annual growth rates across both measures. See our latest analysis for Medline. Despite US$28.4b of revenue and US$1.2b of net income drawing focus to fundamentals, Medline’s recent 1-day share price return of a 3.18% decline and 7-day share price return of an 11.2%...